Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)
Helen Gogas(National and Kapodistrian University of Athens), Keith T. Flaherty(Cancer Research Center), Ivana Krajsová(Charles University), Ana Arance(Hospital Clínic de Barcelona), Mario Mandalà(University of Perugia), Gabriella Liszkay(National Institute of Oncology), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Juliette Murris(Pierre Fabre (France)), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Dirk Schadendorf(National Center for Tumor Diseases), Groot Jan de Willem(Isala), Ashwin Gollerkeri(Peter MacCallum Cancer Centre), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Jeanne Suissa(Pierre Fabre (France)), Paola Queirolo, Carmen Loquai(Johannes Gutenberg University Mainz), Reinhard Dummer(University Hospital of Zurich), Abir Tadmouri Sellier(Pierre Fabre (France)), Claus Garbe(University of Tübingen), Caroline Robert(Institut Gustave Roussy), Naoya Yamazaki(Tokyo National Hospital)
Cited by 15
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k